These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 11380408)
1. Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. Bladé J; Perales M; Rosiñol L; Tuset M; Montoto S; Esteve J; Cobo F; Villela L; Rafel M; Nomdedeu B; Montserrat E Br J Haematol; 2001 May; 113(2):422-4. PubMed ID: 11380408 [TBL] [Abstract][Full Text] [Related]
2. Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide. del Giglio A; Weinschenker P; Manhani AR; Carbonell AL; Mitteldorf CA South Med J; 2005 Feb; 98(2):238-40. PubMed ID: 15759959 [TBL] [Abstract][Full Text] [Related]
3. Thalidomide in refractory and relapsing multiple myeloma. Bladé J; Esteve J; Rosiñol L; Perales M; Montoto S; Tuset M; Montserrat E Semin Oncol; 2001 Dec; 28(6):588-92. PubMed ID: 11740814 [TBL] [Abstract][Full Text] [Related]
4. Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. Avigdor A; Raanani P; Levi I; Hardan I; Ben-Bassat I Leuk Lymphoma; 2001 Aug; 42(4):683-7. PubMed ID: 11697498 [TBL] [Abstract][Full Text] [Related]
5. Extramedullary multiple myeloma escapes the effect of thalidomide. Rosiñol L; Cibeira MT; Bladé J; Esteve J; Aymerich M; Rozman M; Segarra M; Cid MC; Filella X; Montserrat E Haematologica; 2004 Jul; 89(7):832-6. PubMed ID: 15257935 [TBL] [Abstract][Full Text] [Related]
6. [A clinical analysis of 25 cases of multiple myeloma complicated by extramedullary plasmacytomas]. Zhong YP; Chen SL Zhonghua Nei Ke Za Zhi; 2009 May; 48(5):396-8. PubMed ID: 19615158 [TBL] [Abstract][Full Text] [Related]
7. Thalidomide in the treatment of relapsed multiple myeloma. Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Kyle RA; Gertz MA; Greipp PR Mayo Clin Proc; 2000 Sep; 75(9):897-901. PubMed ID: 10994824 [TBL] [Abstract][Full Text] [Related]
8. Progressive myeloma after thalidomide therapy in a patient with immature phenotype of myeloma (plasma) cells. Okikawa Y; Sakai A; Takimoto Y; Noda M; Imagawa J; Katayama Y; Kuroda Y; Okita H; Fujimura K; Kimura A Int J Hematol; 2004 May; 79(4):364-8. PubMed ID: 15218967 [TBL] [Abstract][Full Text] [Related]
9. Primary extramedullary plasmacytoma with diffuse lymph node involvement: a case report and review of the literature. Naymagon L; Abdul-Hay M J Med Case Rep; 2019 May; 13(1):153. PubMed ID: 31113466 [TBL] [Abstract][Full Text] [Related]
10. Lenalidomide is active for extramedullary disease in refractory multiple myeloma. Nakazato T; Mihara A; Ito C; Sanada Y; Aisa Y Ann Hematol; 2012 Mar; 91(3):473-4. PubMed ID: 21647581 [No Abstract] [Full Text] [Related]
12. [Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%]. Wu KL; Schaafsma MR; Lokhorst HM; Wijermans PW; van der Holt B; Sonneveld P Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1445-8. PubMed ID: 12190011 [TBL] [Abstract][Full Text] [Related]
13. Refractory plasmablastic type myeloma with multiple extramedullary plasmacytomas and massive myelomatous effusion: remarkable response with a combination of thalidomide and dexamethasone. Nakazato T; Suzuki K; Mihara A; Sanada Y; Kakimoto T Intern Med; 2009; 48(20):1827-32. PubMed ID: 19834276 [TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of thalidomide in refractory multiple myeloma. Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeddis J; Barlogie B N Engl J Med; 1999 Nov; 341(21):1565-71. PubMed ID: 10564685 [TBL] [Abstract][Full Text] [Related]
15. Discordant response or progression in patients with myeloma treated with thalidomide-based regimens. Anagnostopoulos A; Hamilos G; Zorzou MP; Grigoraki V; Anagnostou D; Dimopoulos MA Leuk Lymphoma; 2004 Jan; 45(1):113-6. PubMed ID: 15061206 [TBL] [Abstract][Full Text] [Related]
16. Lack of response to thalidomide in plasmacytomas. Myers B; Grimley C; Crouch D; Dolan G Br J Haematol; 2001 Oct; 115(1):234. PubMed ID: 11722443 [No Abstract] [Full Text] [Related]
17. Diplopia and variable ptosis as the sole initial findings in a case of orbital plasmacytoma and multiple myeloma. Galea M; McMillan N; Weir C Semin Ophthalmol; 2015 May; 30(3):235-7. PubMed ID: 24164055 [TBL] [Abstract][Full Text] [Related]
18. Response to thalidomide in multiple myeloma: impact of angiogenic factors. Rosiñol L; Cibeira MT; Segarra M; Cid MC; Filella X; Aymerich M; Rozman M; Arenillas L; Esteve J; Bladé J; Montserrat E Cytokine; 2004 May; 26(4):145-8. PubMed ID: 15149630 [TBL] [Abstract][Full Text] [Related]